buprenorphine has been researched along with Head-and-Neck-Neoplasms* in 2 studies
2 other study(ies) available for buprenorphine and Head-and-Neck-Neoplasms
| Article | Year |
|---|---|
The use of transdermal buprenorphine to relieve radiotherapy-related pain in head and neck cancer patients.
Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100 occurred in 26/45 patients 4 weeks after starting cancer therapy, persisting for ≥2 weeks after treatment. These patients subsequently received transdermal buprenorphine. Pain therapy should be more accurately up-titrated to the maximum recommended dose (140 μg/hr) where necessary to maintain pain scores ≤30/100 and, for some patients, should be continued for 6 weeks after the last cancer treatment day. Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Buprenorphine; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Pain; Pain Management; Pain Measurement; Prospective Studies; Radiation Injuries; Radiodermatitis | 2013 |
Transdermal buprenorphine for oropharyngeal mucositis-associated pain in patients treated with radiotherapy for head and neck cancer.
Topics: Administration, Cutaneous; Buprenorphine; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Narcotics; Oropharynx; Pain; Pain Measurement; Stomatitis | 2010 |